UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK

Shields, Adrian M; Anantharachagan, Ariharan; Arumugakani, Gururaj; Baker, Kenneth; Bahal, Sameer; Baxendale, Helen; Bermingham, William; ... Richter, Alex G; + view all (2022) Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK. Clinical and Experimental Immunology 10.1093/cei/uxac008. (In press). Green open access

[thumbnail of uxac008.pdf]
Preview
Text
uxac008.pdf - Published Version

Download (2MB) | Preview

Abstract

In March 2020, the United Kingdom Primary Immunodeficiency Network (UKPIN) established a registry of cases to collate the outcomes of individuals with PID and SID following SARS-CoV-2 infection and treatment. A total of 310 cases of SARS-CoV-2 infection in individuals with PID or SID have now been reported in the UK. The overall mortality within the cohort was 17.7% (n = 55/310). Individuals with CVID demonstrated an infection fatality rate (IFR) of 18.3% (n = 17/93), individuals with PID receiving IgRT had an IFR of 16.3% (n = 26/159) and individuals with SID, an IFR of 27.2% (n = 25/92). Individuals with PID and SID had higher inpatient mortality and died at a younger age than the general population. Increasing age, low pre-SARS-CoV-2 infection lymphocyte count and the presence of common co-morbidities increased the risk of mortality in PID. Access to specific COVID-19 treatments in this cohort was limited: only 22.9% (n = 33/144) of patients admitted to the hospital received dexamethasone, remdesivir, an anti-SARS-CoV-2 antibody-based therapeutic (e.g. REGN-COV2 or convalescent plasma) or tocilizumab as a monotherapy or in combination. Dexamethasone, remdesivir, and anti-SARS-CoV-2 antibody-based therapeutics appeared efficacious in PID and SID. Compared to the general population, individuals with PID or SID are at high risk of mortality following SARS-CoV-2 infection. Increasing age, low baseline lymphocyte count, and the presence of co-morbidities are additional risk factors for poor outcome in this cohort.

Type: Article
Title: Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK
Open access status: An open access version is available from UCL Discovery
DOI: 10.1093/cei/uxac008
Publisher version: https://doi.org/10.1093/cei/uxac008
Language: English
Additional information: © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/)
Keywords: COVID-19, SARS-CoV-2, hypogammaglobulinemia, inborn errors of immunity, primary immunodeficiencies, secondary immunodeficiencies, lymphopenia
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10146766
Downloads since deposit
46Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item